Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel‐resistant cutaneous angiosarcoma: Phase II study protocol
Taku Fujimura,
Koji Yoshino,
Motoki Nakamura
et al.
Abstract:Cutaneous angiosarcoma (CAS) is an endothelial cell‐derived, highly aggressive type of vascular tumour. Although chemoradiotherapy with paclitaxel (PTX) is recognized as a first‐line therapy for CAS, second‐line therapy for CAS remains controversial, and there is no standard therapy for taxane‐resistant CAS. Plasminogen activator inhibitor‐1 (PAI‐1) is associated with poor clinical outcomes, and elevated levels of PAI‐1 in both tissue and serum are correlated with poor response to therapy in various cancers, i… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.